Bladder Cancer Market Share, Size, Forecast 2022

1
Global Bladder Cancer Market - Overview The
global market for bladder cancer is growing at a
steady pace. This can be attributed to increasing
prevalence of bladder cancer. It is reported
that the exact cause of the bladder cancer is not
clear, however, the medical condition is
estimated to be acquainted with certain factors
which are inclusive mutations in the genetic
composition of the patients, continuous exposure
to harmful radiations, and adoption of unhealthy
lifestyle. Such conditions are responsible for
increasing the reported cases of bladder cancer
across the globe. Moreover, factors such as
increasing government support along with the
growing investment in the research and
development process boosts the market growth.
Additionally, rising awareness regarding the
medical condition among the masses also
contributes to the market growth. However, there
factors such as high cost of the treatment in
terms of expensive drugs, and related side
effects are estimated to restrain the market
growth during the projected period. Global
Bladder Cancer Market Share- Competitive
Analysis The Bladder Cancer Market Share is well
established market with number of companies
operating in this market. Bladder Cancer Market
is expected to grow in the presence of increasing
demands for better therapeutics. Currently, the
market is witnessing an unavailability of
absolute treatment. This can be seen as an for
the market players to expand their market. The
players, present in the global bladder cancer
market are focusing on the development of new
products. Such novel products are being designed
with views of cost effectiveness and minimum side
effects. Therefore, many companies in the market
are involved in the development of specific types
of molecules, and novel therapies have adopted
the strategies of the acquisitions, product
launches in order to strive in the competitive
market. Additionally, competition amongst new
entrants is expected to increase the growth for
bladder cancer market over the forecasted
period. In October 2017, Astellas and Seattle
Genetics initiated pivotal trial of Enfortumab
Vedotin for patients with locally advanced or
metastatic urothelial cancer. In May 2017,
AstraZeneca plc received U.S. FDA accelerated
approval for the drug Imfinzi (durvalumab). This
drug is intended to be used for previously
treated patients with advanced bladder
cancer. In February 2017, Bristol-Myers Squibb
received the FDA approval for Opdivo (nivolumab)
in previously treated locally advanced or
metastatic urothelial carcinoma, a type of
bladder cancer. In April 2017, FDA granted
Roches atezolizumab, an accelerated approval as
an initial treatment procedure for treating
patients with advanced bladder cancer. It is the
only immunotherapy paradigm approved for the
treatment of advanced bladder cancer. In May
2017, Eli Lily company announced results of
their drug Cyramzas phase III clinical trial for
Bladder cancer. According to company reports,
around 531 patients with urothelial carcinoma
were treated in the trial, with a statistically
significant improvement in progression-free
survival. With this, Company received huge boost
for the development of this drug in the treatment
of bladder cancer. In May 2017, FDA granted
BAVENCIO (avelumab) approval for a common type of
advanced bladder cancer. The global Bladder
Cancer Market consist of players such as,
Oncogenex (US), Astellas (Japan), Eli Lilly and
Company (US), AstraZeneca (UK), F. Hoffmann-La
Roche (Switzerland), GlaxoSmithKline
2
(UK), Accord Healthcare, Inc.(India), Pfizer
(US), Novartis AG (Switzerland) Bristol-Myers
Squibb company (US) and others. These are some
of the major market players at the forefront of
competition in the global bladder cancer
market. Global Bladder Cancer Market - Regional
Analysis On the basis of the geography, the
global bladder cancer market is segmented into
the four major regions, namely the Americas,
Europe, Asia Pacific, and the Middle East
Africa. The Americas holds the largest share in
the global bladder cancer market. Presence of
huge patient population suffering from bladder
cancer is a major reason behind the same. As per
the American Cancer Society, approximately
79,030 new cases of bladder cancer were reported
in 2017. Moreover, it was estimated that the
disease caused about 16,870 deaths withihn the
U.S. Additionally, factors includfing changing
lifestyle, rising government support, incrteasing
role of cancer care organisations for incraesing
the awareness s also impacts a positive growth in
the global bladder cancer market. Europe
accounts for the second largest market share for
the bladder cancer, which is followed by Asia
Pacific. Asia Pacific is the fastest growing
market owing to the huge population base,
increasing prevalence of bladder cancer, rapidly
developing economies and presence of huge
opportunity for the growth of the market. The
Middle East Africa has the least market share
due to the unavailability of the required
healthcare infrastructure, lack of awareness
among people, and affordability issues due to
presence of the poor economies in Africa
region. About US Market Research Future (MRFR)
enable customers to unravel the complexity of
various industries through Cooked Research
Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market
Research Consulting Services. Contact
us Market Research Future (part of Wantstats
Research and Media Private Limited), 99 Hudson
Street,5Th Floor, New York, New York 10013